Clinical Trial Update: DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 study update (DAREON-9) evaluating tolerability of varying doses of BI 764532 in combination with a single-agent chemotherapy in small cell lung cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Small Cell Lung Carcinoma (SCLC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING